================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
-------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 13, 2003
KERYX BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-30929 13-4087132
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
750 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
(Address of principal executive offices)
212-531-5965
(Registrant's telephone number, including area code)
================================================================================
Item 12. Results of Operations and Financial Condition.
On November 10, 2003, Keryx Biopharmaceuticals, Inc. issued a press
release announcing its financial results for the quarter ended September 30,
2003. The text of the press release, which is attached as Exhibit 99.1, is
incorporated by reference into this Item.
Exhibits
99.1 Press Release Dated November 10, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: November 13, 2003 Keryx Biopharmaceuticals, Inc.
(Registrant)
By: /s/ Michael S. Weiss
----------------------------------------
Michael S. Weiss
Chairman & Chief Executive Officer